Literature DB >> 3080419

Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity.

J Y Chang, T H Tran.   

Abstract

Antithrombin III Basel is a hereditary abnormal antithrombin with normal progressive inhibition activity (normal reactive site) and reduced heparin cofactor activity (impaired heparin binding site). Structures of antithrombin III Basel and normal antithrombin III isolated from the same patient were compared by peptide mapping using the dimethylaminoazobenzene isothiocyanate precolumn derivatization technique. Of the approximately 50 tryptic peptides of normal and abnormal antithrombin III, one peptide comprising residues 40-46 had a different retention time in reversed-phase high performance liquid chromatography. The amino acid sequence of the peptide from antithrombin III Basel had a single substitution of Pro (normal) by Leu (abnormal) at position 41. This substitution is close to an Arg (residue 47) and a Trp (residue 49) which have previously been shown to be critical for heparin binding by antithrombin III. Although additional amino acid substitutions in antithrombin III Basel cannot be ruled out, this Pro-Leu replacement could cause a conformational change by increasing both the helical structure and the hydrophobicity around residue 41. These data suggest that: (i) the heparin binding site of antithrombin III encompasses the region containing residues 41, 47, and 49; and (ii) the impaired heparin cofactor activity of antithrombin III Basel is likely due to a conformational change of the heparin binding site induced by the Pro-Leu substitution at position 41.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080419

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Pleiotropic effects of antithrombin strand 1C substitution mutations.

Authors:  D A Lane; R J Olds; J Conard; M Boisclair; S C Bock; M Hultin; U Abildgaard; H Ireland; E Thompson; G Sas
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  The N-terminal segment of antithrombin acts as a steric gate for the binding of heparin.

Authors:  H L Fitton; R Skinner; T R Dafforn; L Jin; R N Pike
Journal:  Protein Sci       Date:  1998-03       Impact factor: 6.725

3.  Re-formation of disulphide bonds in reduced antithrombin III.

Authors:  X J Sun; J Y Chang
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

Review 4.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

5.  Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.

Authors:  J Y Borg; M C Owen; C Soria; J Soria; J Caen; R W Carrell
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

6.  The complete amino acid sequence of bovine antithrombin (ATIII).

Authors:  H Mejdoub; M Le Ret; Y Boulanger; M Maman; J Choay; J Reinbolt
Journal:  J Protein Chem       Date:  1991-04

7.  Expression of functionally active human antithrombin III.

Authors:  A W Stephens; A Siddiqui; C H Hirs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

8.  Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.

Authors:  D C Rijken; E Groeneveld; C Kluft; H K Nieuwenhuis
Journal:  Biochem J       Date:  1988-10-15       Impact factor: 3.857

Review 9.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

10.  Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation.

Authors:  P Molho-Sabatier; M Aiach; I Gaillard; J N Fiessinger; A M Fischer; G Chadeuf; E Clauser
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.